Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
P649165-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $210.90 | |
P649165-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $290.90 | |
P649165-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $590.90 | |
P649165-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $950.90 | |
P649165-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,500.90 |
Specifications & Purity | 98% |
---|---|
Storage Temp | Store at -20°C |
Shipped In | Ice chest + Ice pads |
Product Description | PFE-360 (PF-06685360) is a potent, selective, brain penetrated and orally active leucine-rich repeat kinase 2 (LRRK2) inhibitor with a mean IC 50 of 2.3 nM in vivo In Vivo PFE-360 (4 mg/kg and 7.5 mg/kg, orally, BID, 10-12 weeks) treatment potently decreases the LRRK2-pSer935/total LRRK2 ratio, with no significant adverse effects . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Sprague Dawley rats (NTac:SD) weighed 225-250 g. Dosage: 4 mg/kg and 7.5 mg/kg ( pharmacokinetics and pharmacodynamics ). Administration: Orally BID for 10-12 weeks. Result: The LRRK2-pSer935/total LRRK2 ratio was significantly decreased at both 1 h and 12 h after dosing. The terminal bodyweights exhibited no significant changes. Form:Solid IC50& Target:IC50: 2.3 nM (LRRK2 in vivo) |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | 1-methyl-4-(4-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidin-5-yl)pyrrole-2-carbonitrile |
---|---|
INCHI | InChI=1S/C16H16N6O/c1-21-9-11(6-12(21)7-17)13-8-18-15-14(13)16(20-10-19-15)22-2-4-23-5-3-22/h6,8-10H,2-5H2,1H3,(H,18,19,20) |
InChi Key | IYQTYHISVSPMSU-UHFFFAOYSA-N |
Canonical SMILES | CN1C=C(C=C1C#N)C2=CNC3=C2C(=NC=N3)N4CCOCC4 |
Isomeric SMILES | CN1C=C(C=C1C#N)C2=CNC3=C2C(=NC=N3)N4CCOCC4 |
PubChem CID | 89915073 |
Molecular Weight | 308.34 |
Enter Lot Number to search for COA:
Solubility | DMSO : 10.42 mg/mL (33.79 mM; Need ultrasonic) |
---|
RIDADR | NONHforallmodesoftransport |
---|